Study Title: A Randomized, Double blind, Placebo Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B cell Lymphoma (DLBCL)
This trial is closed to accrual. For general questions, please contact the Clinical Trials Office.